- Zacks•1 hour ago
Juno Therapeutics Inc. (JUNO) is set to report fourth-quarter 2016 results on Mar 1, after the market closes.
- Motley Fool•2 hours ago
The potential for ozanimod to reshape multiple sclerosis may be worth billions of dollars in annual sales.
- Business Wire•18 hours agoFDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)
Celgene Corporation today announced that the U.S. Food and Drug Administration has expanded the existing indication for REVLIMID 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant .
CELG : Summary for Celgene Corporation - Yahoo Finance
Celgene Corporation (CELG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||118.66 x 200|
|Ask||118.70 x 100|
|Day's Range||118.28 - 119.95|
|52 Week Range||94.39 - 127.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||47.52|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|